Clinical trials: Venous Thromboembolic Event
The Primary Study Objective is to Assess the Efficacy and, Safety of Extended 4-week Heparin Prophylaxis Compared to
ONE WEEK VERSUS FOUR WEEK HEPARIN PROPHYLAXIS AFTER LAPAROSCOPIC SURGERY FOR COLORECTAL CANCER.
Overall, only limited evidence exists regarding the clinical benefit of antithrombotic prophylaxis after laparoscopic surgery for cancer.
- Conditions
- The Primary Study Objective is to Assess the Efficacy and, Safety of Extended 4-week Heparin Prophylaxis Compared to, Prophylaxis Given for 8±2 Days After Planned Laparoscopic, Surgery for Colorectal Cancer.
- Trial name
- PRO-LAPS I (NCT01589146)
- Testing
- Heparin, Low-Molecular-Weight
- Where
- Italy
- Volunteers
- 400 people
- Sponsor
- University Of Perugia
Atrial Fibrillation, Venous Thromboembolism
Edoxaban Management in Diagnostic and Therapeutic Procedures
Patients receiving Novel Oral Anticoagulation (NOACs) undergo diagnostic and therapeutic procedures at a rate of 10% per year. Short half-lives and rapid onset of action allow for short periods of NOAC interruption without…
- Trial name
- EMIT-AF/VTE (NCT02950168)
- Testing
- Edoxaban
- Volunteers
- 1,197 people
- Sponsor
- Daiichi Sankyo
Arthroplasty, Replacement, Knee, Venous Thrombosis
A Study of BIBR 1048 in Prevention of Venous Thromboembolism in Patients With TKR Surgery.
The goal of this study is to evaluate the comparative efficacy and safety of three different doses ( 110 mg, 150 mg, 220 mg) of BIBR 1048 (Dabigatran etexilate) orally, compared to placebo, in prevention of venous thromboembolism…
- Trial name
- NCT00246025
- Testing
- Dabigatran etexilate
- Where
- 38 sites in Japan
- Volunteers
- 512 people
- Sponsor
- Boehringer Ingelheim
Thromboembolism
Rivaroxaban for Treatment in Venous or Arterial Thrombosis in Neonates
The purpose of this study is to find out whether rivaroxaban is safe and effective to use in children age newborn to less than 6 months and how long it stays in the body and how it is used in the body.
- Trial name
- Einstein Jr (NCT02564718)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- 9 sites in Austria, France and 5 more
- Volunteers
- 10 people
- Sponsor
- Bayer
Venous Thromboembolism, Ovarian Neoplasms
Venous Thromboembolic Complications in Ovarian Cancer
Objectives of the study are: To estimate the incidence of venous thromboembolism (VTE) in a cohort of women with suspected ovarian cancer and evaluate changes in the coagulation system in case of benign or malignant disease.
- Conditions
- Venous Thromboembolism, Ovarian Neoplasms, Ovarian Cancer, Deep Vein Thrombosis
- Trial name
- NCT02480790
- Where
- Denmark
- Volunteers
- 98 people
- Sponsor
- Ole Thorlacius-Ussing, MD, DMSc, Professor of Surgery
Gonarthrosis
Role of Femoral Nerve Block on Prevention of Postoperative Deep Venous Thromboembolism
To investigate whether preemptive analgesic of femoral nerve block could prevent deep venous thromboembolism due to inhibiting the excessive release of neutrophil elastase and inflammatory cytokines.
- Trial name
- NCT02411097
- Testing
- femoral nerve block
- Where
- China
- Volunteers
- 120 people
- Sponsor
- General Hospital of Ningxia Medical University
Venous Thromboembolism
Clonal Hematopoiesis of Indeterminate Potential in Venous Thromboembolism
The aim of the study is to investigate the existence of clonal hematopoiesis of indeterminate potential (CHIP) in patients with a history of venous thromboembolism.
- Trial name
- CHIPS (NCT04477564)
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Deep-Venous Thrombosis, Pulmonary Embolism
Evaluation of Anti-Xa Levels in Surgery Patients Receiving Fixed Dose Heparin
The purpose of this study is to determine if fixed dose heparin infusions at a rate of 500 units/hour are sufficient to maintain a target anti-Xa of 0.1-0.35 IU/mL for venous thromboembolism (VTE) prophylaxis in patients…
- Conditions
- Deep-Venous Thrombosis, Pulmonary Embolism, Venous Thromboembolism
- Trial name
- NCT02970032
- Testing
- Real time heparin dose adjustment, Standard heparin dose
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Utah
Thrombosis Embolism, Thromboses, Venous
Cancer-related Venous Thromboembolic Disease - Cohort Study
Venous thromboembolic disease (VTE) is a common (1/1000), potentially serious disease (10% mortality when the clinical presentation is that of pulmonary embolism (PE)).
- Conditions
- Thrombosis Embolism, Thromboses, Venous, Cancer
- Trial name
- CAPE (NCT06393764)
- Testing
- Collection of biological samples
- Where
- France
- Volunteers
- 150 people
- Sponsor
- University Hospital, Brest
Crohn Disease, Ulcerative Colitis
SAVES-IBD: Safety & Efficacy of Aspirin vs. Standard of Care for VTE Prophylaxis After IBD Surgery
Aim to determine if aspirin 81 mg orally twice daily is effective and safe as an extended VTE chemoprophylaxis agent after major abdominal surgery for IBD patients.
- Conditions
- Crohn Disease, Ulcerative Colitis, Venous Thromboembolism
- Trial name
- SAVES-IBD (NCT05104229)
- Testing
- Aspirin 81Mg Ec Tab, Standard of Care
- Where
- United States
- Sponsor
- Stefan Holubar MD MS FACS, FASCRS
Venous Thromboembolism
Characterizing Recurrent Thromboembolism, Major Bleeding and All-Cause Death in Patients With Cancer-Associated Thromboembolism Treated With Rivaroxaban
To estimate the real-world rates of recurrent Venous thromboembolism (VTE), major bleeding and all-cause mortality in patients with Cancer-associated thrombosis (CAT) treated with rivaroxaban
- Trial name
- NCT03214172
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Bayer
Total Knee Replacement Surgery
Single Intravenous Administration of TB-402 for the Prophylaxis of Venous Thromboembolic Events (VTE) After Total Knee Replacement Surgery
The purpose of this study is to evaluate the safety and efficacy of a single administration of TB-402 for the prevention of VTE in patients undergoing knee replacement surgery.
- Trial name
- NCT00793234
- Testing
- TB-402, Enoxaparin
- Where
- 35 sites in Bulgaria, Israel and 5 more
- Volunteers
- 316 people
- Sponsor
- ThromboGenics
COVID, Coronavirus Infection
A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to (SARS-CoV-2) COVID-19 Pandemic
Coagulopathy of COVID-19 afflicts approximately 20% of patients with severe COVID-19 and is associated with need for critical care and death.
- Conditions
- COVID, Coronavirus Infection, Severe Acute Respiratory Syndrome, Thromboembolism, Venous
- Trial name
- RAPID-BRAZIL (NCT04444700)
- Testing
- Therapeutic anticoagulation
- Where
- Brazil
- Volunteers
- 465 people
- Sponsor
- University of Sao Paulo General Hospital
Breast Neoplasms, Venous Thromboembolism
Hemostatic Profiles of Endocrine Therapies for Breast Cancer
The aim of this prospective cohort study is to evaluate the modifications of the biological hemostatic profile associated with the use of endocrine therapy in women with breast cancer (tamoxifen or aromatase inhibitors).
- Trial name
- HEMOBREAST (NCT03381963)
- Where
- Switzerland
- Volunteers
- 100 people
- Sponsor
- University Hospital, Geneva
Venous Thromboembolism, Cancer
Statins to Prevent Cancer Associated Blood Clots
Patients with cancer are at high risk for life-threatening venous thromboembolism (VTE) yet rarely receive anticoagulant prophylaxis due to bleeding risks.
- Conditions
- Venous Thromboembolism, Cancer, Cardiovascular Events
- Trial name
- STAT-CAT (NCT07303816)
- Testing
- Rosuvastatin
- Where
- 9 sites in United States
- Volunteers
- 4,000 people
- Sponsor
- Brigham and Women's Hospital
TBI (Traumatic Brain Injury), VTE (Venous Thromboembolism)
Timing of VTE Prophylaxis in TBI
This study compares the efficacy and complication rates of early (24 hours) versus late (72 hours) VTE prophylaxis administration to TBI patients.
- Trial name
- NCT03081169
- Testing
- Enoxaparin Sodium 150 MG/ML Prefilled Syringe, Heparin
- Where
- United States
- Sponsor
- Loyola University
Multiple Myeloma, Venous Thromboembolism
Validation of the 4TS RAM in the Prevention of Venous Thromboembolism in Patients With Plasma Cell Dyscrasias.
Patients with newly diagnosed symptomatic multiple myeloma per IMWG criteria prior to therapy initiation are enrolled in the study.
- Trial name
- ROADMAP-MM (NCT03405571)
- Testing
- No intervention
- Where
- Greece
- Volunteers
- 800 people
- Sponsor
- University of Athens
Thromboembolism, Venous Thromboembolism
Institutional Registry of Thromboembolic Disease
The purpose of this study is to create an institutional registry of Thromboembolic disease through a prospective survey based on epidemiological data, risk factors, diagnosis, prognosis, treatment, monitoring and survival.
- Conditions
- Thromboembolism, Venous Thromboembolism, Pulmonary Embolism
- Trial name
- IRTD (NCT01372514)
- Where
- Argentina
- Volunteers
- 4,500 people
- Sponsor
- Hospital Italiano de Buenos Aires
Deep Vein Thrombosis, Superficial Thrombophlebitis
DOACT Algorithm Versus AI-Based Decision Models in Oral Anticoagulant Therapy for Vascular Patients
Study using a decision algorithm for the application of an oral anticoagulant calculator in vascular diseases, aimed at validating a clinical decision-support tool for conditions such as deep vein thrombosis, superficial…
- Conditions
- Deep Vein Thrombosis, Superficial Thrombophlebitis, Pulmonary Thromboembolisms, Clinical Decision Support Systems
- Trial name
- DOACT (NCT07290608)
- Testing
- DOACT algorithm, No algorithm, LLM-based tools
- Where
- Brazil
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- ITALO EUGENIO SOUZA GADELHA DE ABREU
Venous Thromboembolism
Comparative Study of Prophylactic Agent for Venous Thromboembolism After Total Knee Arthroplasty
The purpose of this study is to compare the efficacy of two prophylactic agent(aspirin 300mg/day and rivaroxaban 10mg/day) for venous thromboembolism after total knee arthroplasty.
- Trial name
- NCT02271399
- Testing
- acetylsalicylic acid, rivaroxaban
- Where
- South Korea
- Volunteers
- 156 people
- Sponsor
- Hanyang University Seoul Hospital